MedTrace Logo

Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence

NCT07477028 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-17

No results posted yet for this study

Summary

Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power, cross-frequency coupling, and distinct spreading depolarization waves. This prospective, observational feasibility study utilizes rapid-deployment, high-density, noninvasive BCI hardware paired with proprietary AI analytics to detect, classify, and securely archive these terminal neurocognitive signals.

Objectives: (1) Quantify transient gamma-band activity and cross-frequency connectivity post-clinical death; (2) Validate the efficacy of machine learning models for real-time signal classification in high-noise clinical environments; (3) Establish a highly secure, encrypted bio-informational archive of peri-life EEG data.

Design: Prospective, open-label, multicenter, observational cohort (n\>20).

Conditions

  • Terminal Illness
  • End-of-Life Care
  • Death
  • Brain Death
  • Death Anxiety
  • Consciousness
  • Electroencephalography
  • Gamma Oscillations
  • Near-Death Phenomena
  • Cognitive
  • Cognition
  • Memory
  • EEG
  • Severe Acute Trauma

Sponsors & Collaborators

  • Columbia University

    collaborator OTHER

  • Massachusetts Institute of Technology (MIT)

    collaborator UNKNOWN

  • Stanford University

    collaborator OTHER

  • City of Hope Medical Center

    collaborator OTHER

  • Noah Tech, Corp.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2030-09-30
Completion
2035-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07477028 on ClinicalTrials.gov